A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Hormone Receptor Positive, Her-2 Negative Advanced/metastatic Breast Cancer Patients
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) ECOG Performance Status of 0 or 1. 2) Histologic or cytologic diagnosis of metastatic breast cancer. 3) Has received no more than two lines of prior hormonal therapy for advanced nonresectable/ metastatic disease or no more than two lines of prior chemotherapy for advanced nonresectable/ metastatic disease.

You may not be eligible for this study if the following are true:

  • 1) Is currently receiving an investigational agent or has received an investigational agent or used an investigational device within 28 days of study registration. 2) Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to study registration. 3) Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.